Autolus enters $200M equity deal and strategic CAR-T collaboration with BioNTech

Autolus Therapeutics plc

BioNTech invests $200M in Autolus ADS at $6.00 per share, plus $50M upfront under license agreement.
Autolus grants BioNTech exclusive license to certain binders; total potential milestones up to $582M.
BioNTech gets rights to use Autolus' UK manufacturing capacity to accelerate BNT211 into pivotal trials.
BioNTech receives up to mid-single-digit royalty on obe-cel net sales; Autolus retains full control of obe-cel.
BioNTech gains option to co-commercialize AUTO1/22 and AUTO6NG and a board nomination right.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Autolus Therapeutics plc entered into License Agreement with BioNTech SE valued at up to $582 million (effective 2024-02-06).

Action: entry
Agreement: license
Counterparty: BioNTech SE
Value: up to $582 million
Effective: 2024-02-06

Exact text from the filing

On February 6, 2024 (the “ Execution Date ”), Autolus Therapeutics plc (the “ registrant ”) and the registrant’s wholly owned subsidiaries, Autolus Limited and Autolus Holdings (UK) Limited (together, with the registrant, the “ Company ”) entered into a License and Option Agreement (the “ License Agreement ”) with BioNTech SE (“ BioNTech ”)

View on SEC.gov

Browse all material agreements →

Autolus Therapeutics plc filing history →

Source: SEC EDGAR

accession 0001193125-24-027393

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.